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Simple Summary: The purpose of the current in silico planning study is to compare radiation doses
of whole-breast irradiation (WBI) and whole-breast plus regional lymph node irradiation (WBI+RNI)
administered to the regional lymph nodes (RLN) in pN1 breast cancer. Twenty-four participating
institutions were asked to create plans of WBI and WBI+RNI for two dummy cases. In all RLN
regions including supraclavicular lymph node, axillary lymph node, and internal mammary lymph
node, the radiation dose to the RLN was higher in WBI+RNI plan than WBI plan.
Abstract: The purpose of the current in silico planning study is to compare radiation doses of
whole-breast irradiation (WBI) and whole-breast plus regional lymph node irradiation (WBI+RNI)
administered to the regional lymph nodes (RLN) in pN1 breast cancer. Twenty-four participating
institutions were asked to create plans of WBI and WBI+RNI for two dummy cases. To compare target
coverage between the participants, an isodose line equal to 90% of the prescribed dose was converted
to an isodose contour (contour90% iso). The relative nodal dose (RND) was obtained using the ratio of
RLN dose to the target dose. The Fleiss’s kappa values which represent inter-observer agreement
of contour90% iso were over 0.68. For RNI, 6 institutions included axillary lymph node (ALN),
supraclavicular lymph node (SCN), and internal mammary lymph node (IMN), while 18 hospitals
included only ALN and SCN. The median RND between the WBI and WBI+RNI were as follows:
0.64 vs. 1.05 (ALN level I), 0.27 vs. 1.08 (ALN level II), 0.02 vs. 1.12 (ALN level III), 0.01 vs. 1.12 (SCN),
and 0.54 vs. 0.82 (IMN). In all nodal regions, the RND was significantly lower in WBI than in
WBI+RNI (p < 0.01). In this study, we could identify the nodal dose difference between WBI and
WBI+RNI.
Keywords: breast cancer; lymph nodes; radiotherapy planning; randomized trial
1. Introduction
Whole-breast irradiation (WBI) after breast-conserving surgery (BCS) reduces locoregional
recurrence and improves survival in patients with breast cancer [1]. To eradicate microscopic
regional disease, prophylactic regional lymph node irradiation (RNI) is administered along with WBI
in early-stage breast cancer. Including RNI was expected to prevent systemic spreading of cancer and
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to improve the survival of the patient [2]. RNI is regarded as a standard treatment in patients with
four or more axillary lymph node (ALN) metastasis [3]. However, in cases with 1 to 3 positive ALN
(pN1), it remains uncertain whether RNI has a beneficial impact on the survival of the patient [4].
In previous randomized trials, RNI was significantly associated with improved disease-free survival
(DFS) in patients with high-risk node-negative or pN1 breast cancer [5,6]. However, in these studies,
only a small proportion of patients received contemporary systemic treatments such as taxane or
anti-HER2 agents that have been proven to improve locoregional control. It is possible that the benefit
of RNI found in the studies was caused by adopting a less effective systemic treatment. Therefore,
it is necessary to evaluate the prognostic impact of RNI in pN1 breast cancer patients receiving
contemporary systemic treatments.
A phase III randomized trial was initiated by the Korean Radiation Oncology Group (the KROG
1701 study, NCT03269981) to analyze the impact of RNI in pN1 breast cancer patients receiving effective
systemic therapies [7]. The primary objective of the KROG 1701 study was to compare DFS between
WBI and WBI plus RNI (WBI+RNI) in pN1 breast cancer patients who received BCS and taxane-based
chemotherapy. For adequate interpretation of the KROG 1701 study result, it is necessary to ensure
different radiation dose to the regional lymph nodes (RLN) between WBI and WBI+RNI. We performed
this in silico study to compare radiation dose distribution in the RLN between WBI and WBI+RNI
plans among participating institutions of the KROG 1701 study.
2. Results
2.1. General Information
In this planning study, 22 institutions used three-dimensional conformal radiotherapy (3D-CRT)
while 2 hospitals used intensity-modulated radiotherapy (IMRT). For RLN radiotherapy in the
WBI+RNI arm, 6 hospitals included ALN, supraclavicular lymph node (SCN), and internal mammary
lymph node (IMN), while 18 institutions included only ALN and SCN in the treatment volumes.
In each institution, the same fractionation schedule with once-daily radiotherapy was applied for both
treatment arms. The prescription schemes were as follows: a total dose of 50.0 Gy in 25 fractions
(n = 10), 50.4 Gy in 28 fractions (n = 8), 43.2 Gy in 16 fractions (n = 2), 41.6 Gy in 16 fractions (n = 1),
40.5 Gy in 15 fractions (n = 1), 40.05 Gy in 15 fractions (n = 1), and 40.0 Gy in 16 fractions (n = 1).
Distributions of the 24 contour90% iso in both treatment arms are depicted in Figure 1; WBI arm in
Case A (a), WBI+RNI arm in Case A (b), WBI arm in Case S (c), and WBI+RNI arm in Case S (d).
Figure 1. Isodose contours representing 90% of the prescribed dose in each institution for the cases of
(a) WBI arm in Case A, (b) WBI+RNI arm in Case A, (c) WBI arm in Case S, and (d) WBI+RNI arm in
Case S. Abbreviations: WBI, whole-breast irradiation; WBI+RNI, whole-breast irradiation plus regional
nodal irradiation.
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The Fleiss’s kappa values among 24 contour90% iso in all four situations (WBI in Case A, WBI+RNI
in Case A, WBI in Case S, and WBI+RNI in Case S) were over 0.68. The DSC value was calculated
between each institutional contour90% iso and the Ref-contour90% iso. The median DSC value of the
24 institutions for the four situations was as follows: 0.80 for WBI arm in Case A, 0.77 for WBI+RNI
arm in Case A, 0.83 for WBI arm in Case S, and 0.80 for WBI+RNI arm in Case S (Table 1).
Table 1. Comparisons of dose coverage among 24 participating institutions.
Contour90% iso * Dice Similarity Coefficient †
Case Median Volume (Range) Kappa Median (Range)
Case A WBI 511 cc (307–721 cc) 0.77 0.80 (0.51–0.89)
WBI+RNI 766 cc (469–1184 cc) 0.68 0.77 (0.58–0.90)
Case S WBI 745 cc (418–1211 cc) 0.78 0.83 (0.71–0.94)
WBI+RNI 1048 cc (468–1557 cc) 0.71 0.80 (0.68–0.89)
* An isodose line equal to 90% of the prescribed dose was extracted from the radiotherapy plan of each participating
institution. Then, the isodose line was converted to an isodose contour (contour90% iso). † Based on contour90% iso
of 24 participating institutions, a reference isodose contour (Ref-contour90% iso) was created. Dice similarity
coefficient between each institutional contour90% iso and the Ref-contour90% iso was calculated. Abbreviations: WBI,
whole-breast irradiation; WBI+RNI, whole-breast irradiation plus regional nodal irradiation; cc, cubic centimeter.
For the WBI plan, the DSC values were over 0.68 in all institutions except for one. For the
WBI+RNI plan, the DSC values were over 0.68 in all institutions except for four (Figure S1).
2.2. Comparisons of RLN and OAR Dose between the Treatment Arms
In both WBI and WBI+RNI plans, all regions of RLN received various amounts of radiation.
The median values of relative mean radiation dose to RLN ranged between 0.01 and 0.64 for WBI plans
and between 0.72 and 1.12 for WBI+RNI plans. WBI in Case A (a), WBI in Case S (b), WBI+RNI in
Case A (c), and WBI+RNI in Case S (d) are depicted in Figure 2.
Figure 2. Box-and-whisker plots for relative nodal radiation dose according to the regional node
group and treatment arms among 24 participating institutions. (a) WBI in Case A, (b) WBI in Case
S, (c) WBI+RNI in Case A, and (d) WBI+RNI in Case S. Abbreviation: WBI, whole-breast irradiation;
WBI+RNI, whole-breast irradiation plus regional nodal irradiation; ALN I, axillary node level I;
ALN II, axillary node level II; ALN III, axillary node level III; SCN, supraclavicular lymph node;
IMN, internal mammary lymph node.
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Relative IMN radiation dose was different depending on whether the IMN was included in
the treatment volume or not. The median value of the relative radiation dose for IMN was 1.04 in
WBI+RNI plans that included IMN irradiation. In WBI+RNI plans without IMN irradiation, the median
relative IMN radiation dose ranged between 0.07 and 1.02 (Table S1). Regardless of RLN groups,
the relative RLN radiation dose was significantly lower in the WBI treatment arm than in the WBI+RNI
arm (Table 2).
Table 2. Comparisons of relative mean nodal radiation dose between the treatment arms.
Case A (Rt, ALND) Case S (Lt, SLNBx)
Regions WBI WBI+RNI p-Value WBI WBI+RNI p-Value
Axillary level I 0.64 (0.14–1.05) 1.05 (0.68–1.17) <0.01 0.61 (0.09–0.98) 1.03 (0.52–1.19) <0.01
Axillary level II 0.27 (0.02–0.68) 1.08 (0.97–1.15) <0.01 0.51 (0.01–0.89) 1.07 (0.34–1.15) <0.01
Axillary level III 0.02 (0.01–0.33) 1.12 (0.93–1.18) <0.01 0.05 (0.00–0.52) 1.11 (0.14–1.22) <0.01
SCN 0.01 (0.00–0.09) 1.12 (0.69–1.20) <0.01 0.02 (0.00–0.11) 1.11 (0.18–1.24) <0.01
IMN 0.54 (0.05–0.81) 0.82 (0.02–1.15) <0.01 0.49 (0.01–0.86) 0.72 (0.29–1.18) <0.01
The median value of mean relative radiation dose among 24 institutions was presented by nodal groups. The relative
nodal dose is defined as the ratio of nodal dose to the target prescription dose. Values in parentheses present
the range of relative nodal dose for each nodal group. Case A represents a patient with right breast cancer who
received axillary lymph node dissection. Case S is a patient with left breast cancer who underwent sentinel lymph
node biopsy. Abbreviations: Rt, right; ALND, axillary lymph node dissection; Lt, left; SLNBx, sentinel lymph
node biopsy; WBI, whole-breast irradiation; WBI+RNI, whole-breast irradiation plus regional nodal irradiation;
SCN, supraclavicular lymph node; IMN, internal mammary lymph node.
Ipsilateral lung dose was significantly higher in the WBI+RNI than the WBI arm. All values
of lung dosimetric parameters were higher in the WBI+RNI than in the WBI arm. Mean heart dose
ranged between 0.1 Gy and 10.6 Gy in all four plans of Case A and Case S. There was no significant
difference in mean heart dose between the two treatment arms (Table 3).
Table 3. Dosimetric parameters for lung and heart.
Case A (Rt. Breast, ALND) Case S (Lt. Breast, SLNBx)
Parameters WBI WBI+RNI p-Value WBI WBI+RNI p-Value
Ipsilateral lung
V5 Gy (%) 30.2 (15.1–77.6) 46.8 (31.6–99.7) <0.01 28.3 (11.8–81.5) 48.1 (27.8–99.9) <0.01
V10 Gy (%) 20.5 (10.1–44.1) 34.9 (19.2–97.4) <0.01 20.7 (7.4–57.8) 36.7 (17.5–99.9) <0.01
V20 Gy (%) 14.3 (6.1–26.1) 28.2 (7.1–76.5) <0.01 16.3 (3.9–29.0) 28.8 (7.2–74.0) <0.01
V30 Gy (%) 11.6 (2.1–20.5) 20.1 (1.5–38.4) <0.01 12.9 (1.1–23.1) 20.2 (2.7–48.6) <0.01
Mean dose (Gy) 8.8 (4.7–15.3) 13.9 (5.6–27.2) <0.01 8.3 (3.0–16.8) 14.2 (5.4–29.3) <0.01
Heart
Mean dose (Gy) 0.5 (0.1–5.0) 0.9 (0.3–6.8) 0.07 3.7 (0.8–8.9) 4.4 (1.5–10.6) 0.09
Value in parentheses presents range of the value in each parameter. Vx Gy indicates percentage of lung volumes
receiving more than x Gy. Case A represents a patient with right breast cancer who received axillary lymph node
dissection. Case S is a patient with left breast cancer who underwent sentinel lymph node biopsy. Abbreviations:
Rt, right; ALND, axillary lymph node dissection; Lt, left; SLNBx, sentinel lymph node biopsy; WBI, whole-breast
irradiation; WBI+RNI, whole-breast irradiation plus regional nodal irradiation.
However, in the WBI+RNI plan for Case A, the median value of mean heart dose was significantly
higher among institutions that included IMN than those that did not (0.5 Gy vs. 4.7 Gy, p < 0.01).
However, the difference in mean heart dose depending on IMN irradiation was not significant in
Case S (Table S2).
3. Discussion
In this in silico study, we found moderate-to-strong agreement on radiotherapy treatment volume
between the participants for both Case A and Case S. In an evaluation of relative radiation dose for
RLN in both treatment arms, we found that significant proportions of radiation were unintentionally
delivered to ALN level I and IMN in the WBI arm. Nonetheless, relative radiation doses for all RLN
regions were significantly higher in the WBI+RNI arm than in the WBI arm. All dosimetric parameters
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of the ipsilateral lung were higher in the WBI+RNI arm than in the WBI arm. However, the mean
radiation dose for the heart was not significantly different in the two treatment arms.
Prophylactic irradiation of SCN and IMN was provided for patients with pN1 breast cancer
to eliminate microscopic tumor foci in RLN regions [8]. Although previous randomized trials such
as the MA.20 and the EORTC 22922-10925 have shown the benefit of RNI in breast cancer control,
these two studies accrued patients before 2007 when effective modern systemic agents were not easily
available [5,6]. Therefore, the magnitude of the RNI benefit is unclear in pN1 breast cancer patients
who underwent modern systemic therapies. Thus, there was a need to reevaluate the impact of RNI
that reflected the effects of contemporary systemic agents. In a recent study assessing the impact of
RNI among node-positive HER2-positive breast cancer patients who were enrolled in the Adjuvant
Lapatinib And/Or Trastuzumab Treatment Optimisation (ALTTO) trial [9], there was no significant
association between RNI and DFS in patients receiving optimal anti-HER2 targeted therapies [10]. In a
similar vein, the phase III KROG 1701 study has been underway with the aim to compare DFS between
WBI and WBI+RNI in patients receiving taxane-based chemotherapy and molecular subtype-specific
treatment, including endocrine therapy or anti-HER2 therapies. In the previous trials, the extents of
RNI varied among the studies. RNI was performed, including both SCN and IMN in the MA.20 and
EORTC 22922-10925 trials; SCN and/or IMN was covered in RNI among patients participating in the
ALTTO trial. Because the extent of RNI might have an influence on DFS, it is necessary to take account
of the RNI extent in the evaluation of the trial outcomes. Moreover, the quality of radiotherapy among
the participating institutions should be assured to analyze the impact of RNI accurately.
In this study, the 24 participating institutions of the KROG 1701 study were requested to create
radiotherapy plans for two cases. The two cases were set up to represent each side of breast cancer
and the two methods for ALN management: Case A had ALND for right breast cancer, while Case
S received SLNBx for left breast cancer. By comparing each institutional contour90% iso for the two
cases, we aimed to evaluate patterns of radiotherapy planning and agreement of dose coverage
among the participants. In other dummy run studies of phase III randomized trials on RNI for
breast cancer, a comparison of IMN radiation dose between the treatment arms was the main focus
of interest [11,12]. Unlike these studies, we compared the radiation dose for the whole breast and all
groups of RLN depending on treatment arms among the participating institutions. The Fleiss’s kappa
values were over 0.68 among 24 contour90% iso in all four situations. Further, values of DSC between
the Ref-contour90% iso and each institutional contour90% iso were over 0.68 in all but two institutions.
In these two institutions, the DSC value was under 0.6 in both plans for WBI and WBI+RNI.
By comparing the nodal radiation dose between the arms, we found that all nodal groups received
a larger radiation dose in the WBI+RNI arm than in the WBI arm. The RND tends to be larger than 1 in
most of the WBI+RNI plans. Three-field techniques, which were used for WBI+RNI, frequently result
in an overdose area in the filed junction. The overdose areas are probably attributable to the RND ≥ 1
in our study. The RLN radiation dose was different depending on the extent of the radiotherapy
field. In WBI+RNI, the relative nodal dose in IMN differed based on whether IMN was included
in the treatment volume or not. Moreover, the radiation dose to ALN level I differed based on the
use of IMN irradiation. Thus, the dosimetric effect of IMN radiotherapy should be considered while
interpreting the outcomes of the KROG 1701 study in the future. Further, we found in this study
that IMN receives 5–80% of the prescription dose even in WBI. In the dummy run of the EORTC
22922-10925 trial, radiation dose in the IMN was less than 50% of the prescription dose in over 94% of
the plans of the WBI group [11]. Another dummy run study of a randomized trial on IMN irradiation
(KROG 08-06 study) reported that mean radiation dose to IMN was 40–74% of the prescription dose
in the WBI arm [12]. The dummy run of the EORTC 22922-10925 trial evaluated point dose rather
than a volumetric dose of the IMN. Additionally, radiation dose distributions were checked in three
slices of simulation computed tomography (CT) and not all slices of CT [11]. Therefore, the radiation
dose to IMN might be over- or under-estimated in the dummy run of the EORTC 22922-10925 trial.
In the dummy run of the KROG 08-06 study [12], the range of IMN radiation dose in WBI was smaller
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than that in our study. The dummy run of the KROG 08-06 study was performed in 12 institutions,
whereas the current planning study was conducted in 24 institutions. It is probable that due to the
larger number of participating institutions in our study, the range of IMN radiation dose was larger
than that in the dummy run of the KROG 08-06 trial.
We found that all dosimetric parameters of the ipsilateral lung were higher in the WBI+RNI than in
the WBI arm. This can be related to lung toxicity. In a previous study on prophylactic SCN irradiation
in pN1 breast cancer, a higher frequency of grade I pneumonitis was observed in the case of SCN
radiotherapy with WBI than in WBI alone [13]. Even though lung toxicity might not be severe after
WBI+RNI, the radiotherapy plan should be modified to minimize lung dose. We recognized that the
mean heart dose was not significantly different between the two arms in this planning study. Among the
KROG 1701 study participants, only a quarter of the institutions included IMN in the treatment field
for WBI+RNI plan. The mean heart dose was higher in institutions performing IMN-including RNI
than that in those performing IMN-excluding RNI. However, statistical significance was noted only
in Case A and not in Case S. The location of IMN and the patient’s geometric characteristics might
have contributed to the difference in statistical significance between Case A and Case S. The range of
mean heart dose was found to be large in this study. Since the mean heart dose in the contemporary
radiotherapy era was reported to be <5 Gy [14,15], the mean heart dose noted in some institutions
among our participants is thought to be high. The relative risk of major coronary events increases
linearly with increasing mean heart dose (7.4% per Gy) [14]. Therefore, heart dose should be minimized
whenever possible. In addition, we recognized that further efforts including education and feedback
are needed to enhance homogeneity of radiation planning among participating institutions.
4. Materials and Methods
4.1. Cases
Investigators of the 24 participating institutions were asked to generate radiotherapy plans for
two cases with pN1 breast cancer. Planning computed tomography (CT) images of two de-identified
patients were used for this planning study. Details of the two cases are described in Table 4.
Table 4. Details of the cases.
Case Description
Case A
43 years old. She received partial mastectomy and sentinel lymph node biopsy for right breast
cancer. Intraoperative frozen sections of sentinel lymph nodes revealed metastatic carcinoma in 2
out of 3 sentinel lymph nodes. Complete axillary lymph node dissection was performed.
The pathology showed a 2.5-cm-sized invasive ductal carcinoma of the breast. In the specimen of
axillary lymph node dissection, there was no metastatic carcinoma in the lymph nodes.
Case S
40 years old. She received partial mastectomy and sentinel lymph node biopsy for cT1N0 cancer in
the left breast. Intraoperative frozen sections of sentinel lymph nodes revealed metastatic
carcinoma in 1 out of 4 sentinel lymph nodes. Axillary lymph node dissection was not performed.
Pathology showed a 1.2-cm-sized invasive ductal carcinoma of the breast.
Briefly, one case (Case A) is of a patient with right breast cancer who received sentinel lymph node
biopsy (SLNBx) followed by axillary lymph node dissection (ALND) and the second case (Case S) is of
a patient with left breast cancer who underwent SLNBx only. CT images of the cases were downloaded
from a website by the participants and loaded into each institutional treatment planning system.
According to the radiotherapy guidelines of the KROG 1701 study (Table S3), each participant generated
radiotherapy plans for both treatment arms, WBI and WBI+RNI, for the two cases. Thus, a total
of four plans were created by each participating institution. Then, the participants were asked to
upload the planning CT, structure sets, and radiotherapy plans to a website in the Digital Imaging
and Communications in Medicine format. Planning for tumor bed boost was not required in this
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study. The study was approved by the Institutional Review Board of Samsung Medical Center,
SMC 2017-01-085-001.
4.2. Data Analysis
To analyze the target dose coverage, an isodose line equal to 90% of the prescribed dose was
extracted from the radiotherapy plan of each participating institution. Then, the isodose line was
converted to an isodose contour (contour90% iso). An agreement of contour90% iso among the participating
institutions was assessed by the Computational Environment for Radiotherapy Research software [16].
Further, based on the contour90% iso of 24 participating institutions, a reference isodose contour
(Ref-contour90% iso) was created by the simultaneous truth and performance level estimation (STAPLE)
algorithm (Figure S2) [17]. The isodose contour of WBI in Case A (a), WBI+RNI in Case A (b), WBI in
Case S (c), and WBI+RNI in Case S (d) are presented in Figure S2.
A similarity between each institutional contour90% iso and the Ref-contour90% iso was evaluated
by calculating Dice similarity coefficient (DSC) using the 3D Slicer software [18]. The value of a DSC
ranges from 0, which refers to an absence of spatial overlap between two samples, to 1, which refers to
complete overlap. To assess radiation dose to the RLN according to treatment arms, a relative mean nodal
radiation dose of each RLN was acquired. The relative nodal dose is defined as the ratio of RLN dose to
the target prescription dose. RLN groups including ALN, supraclavicular lymph node (SCN), and/or
internal mammary lymph node (IMN) were delineated according to the ESTRO (European Society for
Radiotherapy and Oncology) consensus guideline [19] by two radiation oncologists (H. Kim and J.Y. Baek).
Using dose–volume histograms for the heart and lungs, dosimetric parameters of organs-at-risk
(OAR) were evaluated. Mean lung and heart doses and lung volumes receiving more than 5 Gy
(V5 Gy), 10 Gy (V10 Gy), 20 Gy (V20 Gy), and 30 Gy (V30 Gy) were analyzed. Because various fractionation
schemes were used among participating institutions, radiation dose was converted to the biologically
equivalent dose in 2 Gy fractions (EQD2) assuming the α/β ratio of 3 Gy for OAR [20].
4.3. Statistical Analysis
An agreement of contour90% iso among the participating institutions was assessed using Fleiss’s
Kappa method [21]. The Kappa value ranges between 0, which refers to no agreement, and 1,
which refers to perfect agreement [22]. The Wilcoxon signed-rank test was performed to evaluate
differences in RLN and OAR radiation doses between the two treatment arms. Statistical analyses
were conducted using MedCalc Statistical Software version 18.11.3 (MedCalc Software bvba,
Ostend, Belgium), and p-values < 0.05 were considered statistically significant.
5. Conclusions
In this study, we found that radiation doses for all nodal regions were significantly higher in the
WBI+RNI than in the WBI. Through this in silico planning study, we could identify the nodal dose
difference between the two treatment arms of the KROG 1701 study.
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